Title: Reduced Onset of MASLD, MASH, and Advanced Liver Disease in patients who received Individualized Nutrition-Focused Remote Care for Adults with Type 2 Diabetes and Obesity

Authors:
Shaminie J Athinarayanan, PhD [1], Adam J Wolfberg MD [1], Priya V Shanmugam PhD [1], Bilal A Hameed [2], Maurizio Bonacini [3]

Affiliations
[1] Research Department, Virta Health, Denver, CO
[2] Transplant Hepatology, School of Medicine, University of California, San Francisco
[3] Mission Gastroenterology and Hepatology, University of California, San Francisco

Author Contributions

SJA conceived and designed the study, conducted the statistical analyses, and took the lead in drafting the manuscript. PVS and SJA were responsible for data acquisition and curation. MB and AJW contributed to the study design and concept development. AJW, BAA, PVS, and MB provided clinical and scientific guidance and contributed to the interpretation of the results. All authors critically reviewed, revised, and approved the final version of the manuscript.

Address for correspondence

Shaminie J Athinarayanan, Virta Health, 3513 Brighton Blvd, Suite 310, Denver, CO 80216, USA, Email: shaminie@virtahealth.com

Financial support and sponsorship: None. This study was a retrospective analysis of deidentified claims data

Conflicts of interest: SJA, PVS, and AJW are full-time employees of Virta Health, and have been granted stock options. All remaining authors report no financial or professional relationships that could be perceived as potential conflicts of interest related to the study's data, analysis, interpretation, or reporting.

Keywords: Nutrition, MASLD, MASH, remote care, liver related events

Abbreviations: T2D, type 2 diabetes; VINT, Virta Individualized Nutrition Therapy; UC, usual care; LRE, liver related event; MASLD, metabolic dysfunction–associated steatotic liver disease; MASH, metabolic dysfunction–associated steatohepatitis; PHTN, portal hypertension; HCC, hepatocellular carcinoma; BHB, beta hydroxybutyrate

Abstract

Background and Aims

Metabolic dysfunction–associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction–associated steatohepatitis (MASH), lead to significant morbidity and mortality in adults with type 2 diabetes (T2D) and obesity. This study evaluated whether participation in an individualized, nutrition-focused telemedicine care model emphasizing carbohydrate reduction (Virta Individualized Nutrition Therapy, VINT) was associated with reduced onset of MASLD, MASH, and advanced liver disease.

Approach and Results

Adults with T2D, prediabetes, overweight, or obesity who enrolled in VINT (2015–2024) were identified in the Komodo Healthcare Map and matched 1:1 to usual care (UC) controls (n = 5,031 per group). Using three complementary analytic approaches, incidence and time-to-event analyses were performed for new-onset liver disease. Across all strategies, VINT participants consistently showed lower incidence of any liver-related diagnosis (29.9 vs 44.9 per 1,000 person-years; HR = 0.64, $p < 0.001$), MASH and beyond (4.2 vs 10.7; HR = 0.38, $p < 0.001$), and advanced liver disease (2.8 vs 9.0; HR = 0.30, $p < 0.001$). VINT participants who lost ≥15% body weight were at lower risk of new-onset liver disease (21.2 vs 31.8 per 1,000 person-years; HR = 0.66, $p = 0.02$) compared to VINT participants who lost less weight.

Conclusions

Participation in individualized nutrition-focused telemedicine care was associated with significantly lower incidence and risk of new-onset MASLD, MASH, and advanced liver disease. These findings support scalable, lifestyle-first interventions to reduce liver disease burden in adults with T2D and obesity.

Infographic



Plain Language Summary

People with type 2 diabetes and obesity are more likely to develop liver conditions such as metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH), which can progress to liver failure or liver cancer. This study examined whether a nutrition-focused remote care program could help prevent these liver diseases. The Virta Individualized Nutrition Therapy (VINT) program uses telemedicine and personalized, carbohydrate-reduced nutrition to support long-term weight loss and metabolic health. Using health claims data, researchers compared more than 5,000 participants in the VINT program with matched individuals receiving usual care. Those in the VINT group had significantly fewer new cases of MASLD, MASH, and advanced liver disease. Participants who lost 15% or more of their body weight were especially protected. These findings suggest that individualized, nutrition-based remote care can help prevent liver disease in people with type 2 diabetes and obesity.

Introduction

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its more progressive form, metabolic dysfunction-associated steatohepatitis (MASH), are major public health concerns in the United States. Approximately one-third of U.S. adults are affected by MASLD, with prevalence rising to 55–70% among individuals with type 2 diabetes and those who are overweight or obese (1–4). Modeling studies suggest that ~20% of individuals with MASLD progress to MASH, corresponding to ~15 million U.S. adults who are at risk for cirrhosis, liver failure, hepatocellular carcinoma (HCC), and increased cardiometabolic complications (5,6). The economic burden exceeds $300 billion annually, reflecting both direct medical costs and lost productivity (7,8).

Weight loss of ≥7–10% of body weight is strongly associated with histologic improvements in MASLD/MASH, including resolution of steatohepatitis and regression of fibrosis (8). Accordingly, current guidelines emphasize intentional weight loss as the cornerstone of therapy for MASLD/MASH (9-11). Pharmacologic agents such as resmetirom (12) and semaglutide (13) are currently recommended by the FDA as adjuncts to weight loss because the latter remains the first-line intervention and the most consistently reliable approach associated with both MASH resolution and fibrosis regression.

The Virta Individualized Nutrition Therapy (VINT), which delivers telemedicine-based remote care, health coaching, and carbohydrate-reduced nutrition therapy with an emphasis on nutritional ketosis, has demonstrated durable weight loss and metabolic improvements across type 2 diabetes, prediabetes, and overweight/obesity populations in both clinical trials and real-world settings (14-18). Post-hoc analyses of the clinical trial data further revealed significant

improvements in liver health, including normalization of alanine aminotransaminase (ALT) in 61% of those with elevated baseline values, reductions in aspartate transaminase (AST) and alkaline phosphatase (ALP), and improvements in surrogate NAFLD markers. 20% fewer participants met criteria for suspected steatosis and 15% fewer classified as not having suspected fibrosis after one year (19).

A reduction in new-onset liver-related events (LREs) is the endpoint established by the FDA to support full approval for medications such as resmetirom or semaglutide, which are currently only conditionally approved. To address this gap, we analyzed claims data to assess the incidence of new-onset MASLD, the development of new-onset MASH (including cases that may have progressed from a prior MASLD diagnosis), and advanced liver disease among patients enrolled in VINT. For this purpose, we leveraged ICD-10 diagnostic codes to identify clinically meaningful endpoints at the population level.

Materials and Methods

Data Source

This study utilized data from the Komodo Healthcare Map™, a nationwide commercial administrative claims database in the United States that captures pseudonymized medical, pharmacy, and laboratory claims across a large, representative segment of the insured population (20). For this analysis, tokenized demographic records, generated using privacy preserving encryption to enable linkage of deidentified patient data across datasets, along with enrollment and follow up variables for treated participants, were linked to their corresponding claims within the Healthcare Map™. A control population of 2.39 million patients was identified from the same database to generate the matched control cohort. The dataset iteration dated August 25,

2025, was used, and all analyses were conducted within Sentinel, Komodo Health's secure real world evidence platform.

Study Population, Intervention and Medication Management

This analysis included adults (≥18 years) with type 2 diabetes (T2D), prediabetes, overweight, or obesity who enrolled in the Virta Individualized Nutrition Therapy (VINT) program for diabetes reversal or sustainable weight loss between August 2015 and September 2024. Participants were required to remain enrolled for at least one year after the index date. Individuals with conditions in which nutritional ketosis is contraindicated (for example, type 1 diabetes, active malignancy, or pregnancy) were excluded as part of the program exclusion criteria. Detailed program eligibility criteria and a full description of the intervention are provided in the Supplementary Methods.

The intervention is delivered through a fully remote, continuous care model that integrates individualized nutrition therapy, protocol guided medication management, and health coaching via a telemedicine platform. The dietary approach centers on individualized carbohydrate reduction to induce and maintain nutritional ketosis (target beta hydroxybutyrate (BHB) 0.5 to 3.0 mmol/L), with moderate protein intake of approximately 1.2 to 1.5 g per kilogram of reference body weight per day and dietary fat to satiety as the primary energy source. The program emphasizes whole, minimally processed foods and is supported by structured education in nutrition, behavior change, and lifestyle adaptation. Participants receive ongoing real time support from licensed medical providers and health coaches through the digital platform.

Medication adjustments were managed by VINT clinicians to ensure safety during reductions in dietary carbohydrate intake. Agents with higher hypoglycemia risk (such as insulin and

sulfonylureas) were typically reduced at initiation, whereas other therapies, including antihypertensives and diuretics, were titrated as clinically indicated. Biomarkers (blood glucose, BHB, and body weight) were monitored daily at program initiation, particularly during the first three months, and were thereafter individualized to each participant's preferences and tolerance of the nutritional intervention; treatment decisions, including deprescribing or reinitiation, were guided by these data and direct provider oversight.

Claims Analysis

For the claims-based analyses, both VINT participants and controls were required to have continuous medical and pharmacy claims coverage defined as no gap greater than 30 days for at least one year prior to the enrollment or index date and at least six months after. Control participants were assigned a randomly generated index date aligned with the distribution of enrollment dates in the VINT cohort to ensure temporal comparability. Baseline measures included in the matching encompassed demographic characteristics (age, sex, and race/ethnicity), clinical comorbidities, medication use, and healthcare costs. Comorbidities were identified using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes appearing in either primary or secondary positions within medical claims (see Supplementary Table S1). Several liver conditions were excluded at baseline before matching (details in the supplementary method and Supplementary Table S1). Individuals with MASLD, MASH, and fibrosis were retained to allow evaluation of new-onset and progression outcomes within these at-risk populations. Medication classes assessed at baseline and follow-up are detailed in Supplementary Table S2.

Study Outcomes

The primary composite outcomes were defined as the time to new onset of:

1. Any liver-related diagnosis, defined as a composite endpoint including MASLD, MASH, liver fibrosis, cirrhosis, portal hypertension (PHTN) and its complications (ascites, varices, or hepatic encephalopathy), HCC, other abnormal liver imaging findings, or inflammatory liver disease.
2. "MASH and beyond," defined as a composite endpoint including MASH, fibrosis, cirrhosis, PHTN, PHTN complications, and HCC.
3. Advanced liver disease, defined as a composite endpoint including fibrosis, cirrhosis, PHTN, PHTN complications, and HCC.

"New onset" was defined as the first occurrence of the outcome after the index date among participants who met the strategy-specific baseline exclusion criteria. Follow-up was limited to 5 years and was right-censored at the time a liver-related event occurred, at the end of the closed claims period, or at the study end date if no outcome occurred.

Analyses were conducted using three complementary analytic strategies to assess robustness and consistency. Analytic strategy 1 (incident disease cohort) excluded participants with baseline MASLD, MASH, or fibrosis and evaluated all three composite outcomes: any liver-related diagnosis, MASH and beyond, and advanced liver disease. Analytic strategy 2 (incident disease and potential MASLD progression cohort) excluded participants with baseline MASH or fibrosis (allowing baseline MASLD) and evaluated two composite outcomes: MASH and beyond, and advanced liver disease. Analytic strategy 3 (incident disease cohort with maximally restricted baseline) excluded all participants with baseline evidence of liver disease defined as MASLD,

MASH, fibrosis, or findings suggestive of liver disease based on imaging, biopsy, or elastography procedure codes and evaluated the any liver-related, MASH-and-beyond and advanced liver disease composite outcomes. For the MASH-and-beyond and advanced liver disease analyses, other liver-related diagnoses identified during follow-up (e.g., MASLD, abnormal liver imaging, or inflammatory liver disease) were not counted as events, ensuring a clean assessment of the prespecified composite endpoints.

Secondary outcome analyses were restricted to the VINT cohort. We evaluated whether categorical clinical variables including mean BHB level over 6 months (≥0.3 vs <0.3 mmol/L and ≥0.5 vs <0.5 mmol/L), 6-month weight change (≥10% loss vs <10% loss and ≥15% loss vs <15% loss), and HbA1c change at 1 year (or 6 months if 1-year data were unavailable; ≥0.5 percentage point reduction vs <0.5 point reduction or any increase) were associated with the primary composite outcome of new onset of any liver related diagnosis, as defined in analytic strategy 1.

Exploratory outcomes characterized healthcare utilization and liver-specific procedures (e.g., ultrasound, elastography, CT/MRI, biopsy), comparing intervention participants with matched controls. For the MASLD, MASH, and fibrosis subgroups, we also conducted a descriptive evaluation of concomitant pharmacotherapy among participants with evidence of disease at baseline or who developed MASLD or MASH during follow-up. Medication classes were defined a priori and included metabolic and liver-directed therapies (e.g., GLP-1 receptor agonists, SGLT2 inhibitors, thiazolidinediones [pioglitazone], vitamin E, and statins).

Statistical analysis

This study was conducted and reported in accordance with the STROBE guidelines for observational research (21), with a completed checklist included in the Supplementary Material. A detailed description of the statistical analysis is in the supplementary methods. Baseline characteristics are summarized as mean (SD) for continuous variables and n (%) for categorical variables. Between group balance is described using standardized mean differences (SMD) with SMD ≤0.10 indicating adequate balance (no hypothesis tests for baseline).

Primary composite time-to-event outcomes (definitions provided in *Study Outcomes*) were analyzed using Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), comparing VINT participants with matched controls. For matched analyses, stratified Cox models were applied by matched set, with robust standard errors clustered on matched pairs to account for within-set correlation. All models were adjusted for age, sex, and race/ethnicity. Extended models further adjusted for baseline diagnoses of type 2 diabetes and obesity, as well as follow-up use of cardiometabolic medications with potential hepatic effects, including SGLT2 inhibitors, GLP-1 receptor agonists, statins, and other relevant agents. Medication use was modeled both as categorical ever/never exposure and as continuous proportion of days covered (PDC) to capture adherence.

Kaplan–Meier cumulative incidence curves were generated to visualize differences between groups, with numbers at risk displayed at prespecified time points. Incidence rates were calculated as events per 1,000 person-years. Absolute risk reduction (ARR) was computed as the difference in incidence rates between the UC and VINT groups, and the number needed to treat (NNT) was derived as the reciprocal of ARR (1/ARR), representing the number of individuals

who would need to receive VINT for one year to prevent one additional new-onset liver diagnosis compared with UC. To assess robustness, sensitivity analyses were performed using inverse probability of treatment weighting (IPTW) with stabilized weights. Weighted Cox proportional hazards models with robust variance estimators were then used to estimate HRs in the pseudo-population generated by IPTW.

Secondary outcomes within the VINT cohort were evaluated using five separate Cox models to assess the associations of: (i) mean BHB ≥0.3 vs <0.3 mmol/L (with missing values grouped with <0.3), (ii) mean BHB ≥0.5 vs <0.5 mmol/L (with missing values grouped with <0.5), (iii) 6-month weight change ≥10% vs <10%, (iv) 6-month weight change ≥15% vs <15%, and(v) HbA1c change ≥0.5 vs <0.5 percentage points (at 6 or 12 months)with the post-index primary outcome of new onset of all liver diagnoses defined by strategy 1. Incidence rates were compared across weight-loss categories using Poisson regression to estimate rate ratios and 95% confidence intervals, with the <5% weight-loss group as reference. For prevalence comparisons, Chi-square and Cochran–Armitage trend tests were used to assess differences and linear trends across increasing weight-loss categories

Exploratory analyses included a subcohort of participants with baseline MASLD, MASH, or fibrosis and at least one follow-up diagnosis recorded on a new date. Transitions between liver disease states were evaluated descriptively. Liver-specific imaging, procedures, and biopsy were assessed descriptively in the matched cohort, with overall distributions compared using Wilcoxon rank-sum tests. Medication use was evaluated across predefined metabolic and liver-directed therapy classes (e.g., GLP-1 receptor agonists, SGLT2 inhibitors, thiazolidinediones [pioglitazone], vitamin E, statins, and other supplements with liver benefits). The proportion of participants with any exposure and the cumulative duration of use (mean and median days

covered) were summarized, and between-group differences were assessed to contextualize treatment patterns.

All statistical tests were two-sided ($\alpha = 0.05$) with 95% confidence intervals (CIs), and analyses were conducted using R software (R packages used are listed in the Supplementary statistical method section).

Results

Study Participants Flow

Within the Komodo Sentinel claims environment, the initial study population included 78,755 individuals in the intervention cohort and 2.39 million in the control cohort (Figure 1). After applying the closed claims requirement, 10,170 intervention participants and 509,727 controls remained. Following the additional eligibility criteria of at least one year of continuous program enrollment, a minimum of six months of claims data follow up and after excluding some baseline comorbidities or conditions, 5,236 intervention participants and 200,778 controls met inclusion requirements and were retained for propensity score matching (Figure 1; Supplementary Table S3).

Baseline Characteristics

After 1:1 propensity score matching, the analytic sample consisted of 5,031 VINT participants and 5,031 controls (usual care, UC) (Figure 1; Tables 1 and 2), representing roughly 10% of the original dataset with similar tenure. To assess representativeness, the matched VINT cohort was compared with VINT participants excluded during screening. Baseline demographics and aggregated variables were broadly similar, with most standardized mean differences (SMDs) ≤

0.1, aside from race and ethnicity and the program that enrolled in either diabetes reversal or sustainable weight loss (SMD < 0.2) (Supplementary Table S4). Post-matching, baseline characteristics were well balanced between VINT and UC across all covariates used in the matching (all SMDs ≤0.1) as well as most comorbidities, clinical conditions, and medications not directly included in the matching process (Tables 1 and 2). The matched cohorts had a mean age of 53 years, and the distribution of males and females was similar between the groups. At baseline, 5.1% of participants had MASLD/MASH (including fibrosis), 51% had type 2 diabetes, and 36% had obesity. Mean follow-up was 2.2 years in the VINT group and 1.9 years in the UC group. Although the mean follow-up duration was shorter in the UC group, survival analyses inherently accommodate unequal follow-up by using time-to-event with right censoring; thus, estimates remain unbiased under non-informative censoring. Furthermore, the selection of index dates for UC was aligned with the distribution of VINT enrollment dates. This approach ensured that seasonal patterns, temporal shifts, or year-specific effects were accounted for, as illustrated by the overlapping distribution of index dates between groups (Supplementary Figure 1).

Primary outcomes

Across all analytic strategies, VINT participants had consistently lower incidence rates of new-onset any liver-related diagnoses compared with UC. Under strategy 1, the rates were 29.9 vs 44.9 per 1,000 person-years (HR = 0.64; 95% CI 0.55–0.75; $p < 0.001$; Figure 2A), and under strategy 3, 29.9 vs 44.5 (HR = 0.65; 95% CI 0.55–0.76; $p < 0.001$; Figure 2B). These associations remained significant and of similar or greater magnitude after adjustment for medication use (Table 3). Based on incidence rates, the corresponding absolute risk reductions were approximately 15 fewer events per 1,000 person-years, yielding NNTs of 67–68 per year.

For new-onset MASH and beyond, incidence rates were consistently lower among VINT participants across all three analytic strategies: 4.2 vs 10.7 per 1,000 person-years (HR = 0.38; 95% CI 0.27–0.56; $p < 0.001$; Figure 2C) under strategy 1; 4.7 vs 11.5 (HR = 0.38; 95% CI 0.27–0.56; $p < 0.001$; Figure 2D) under strategy 2; and 4.2 vs 10.7 (HR = 0.37; 95% CI 0.25–0.55; $p < 0.001$) under strategy 3. These findings remained significant and directionally consistent following adjustment for medication use (Table 3). Based on incidence rates, absolute risk reductions ranged from 6.4–6.8 events per 1,000 person-years, corresponding to NNTs of 147–156 per year.

For new-onset advanced liver disease, VINT participants again demonstrated substantially lower incidence rates: 2.8 vs 9.0 per 1,000 person-years (HR = 0.30; 95% CI 0.19–0.47; $p < 0.001$; Figure 2E) under strategy 1; 3.3 vs 9.7 (HR = 0.32; 95% CI 0.21–0.49; $p < 0.001$; Figure 2F) under strategy 2; and 2.9 vs 9.0 (HR = 0.30; 95% CI 0.19–0.48; $p < 0.001$) under strategy 3. The corresponding absolute risk reductions were 6.1–6.4 fewer events per 1,000 person-years, yielding NNTs of 156–163 per year. As summarized in Table 3, the hazard ratios remained robust after adjustment for medication exposure

Diagnostic distribution at follow-up events (Figures 3A–3C; overall cohort by analytic strategy) showed UC had a greater proportion of advanced/later-stage liver diagnoses than VINT. In a separate subcohort with baseline MASLD/MASH/fibrosis and a follow-up date-coded diagnosis (Supplementary Table S5), most participants remained in the same diagnostic category, with higher stability in VINT (74.3%) than UC (69.6%); transitions to nonspecific or advanced diagnoses were infrequent and were similar or slightly lower in VINT.

Sensitivity analyses using IPTW-weighted Cox regression produced consistent results, which are presented in Supplementary Table S6.

Secondary outcomes

In the VINT cohort, weight loss of ≥15% was significantly associated with a reduced risk of new onset liver disease in demographic-adjusted models (incidence rate 21.2 per 1,000 person-years in ≥15% vs 31.8 per 1,000 person-years in <15%; HR = 0.66, 95% CI: 0.46–0.95, p = 0.02). In contrast, weight loss of ≥10% was marginally significantly associated with risk reduction (HR = 0.78, 95% CI: 0.61–1.00, p = 0.05). After further adjustment for medication use, the association for ≥15% weight loss was attenuated (HR = 0.67, 95% CI: 0.46–0.97, p = 0.04 for categorical medications; HR = 0.73, 95% CI: 0.51–1.04, p = 0.08 for continuous PDC medications). A dose–response relationship was observed across weight-loss categories, with lower incidence (Figure 4A) and prevalence of liver disease at greater weight reduction (Figures 4B). Only the ≥15 % group showed a significantly lower incidence rate versus <5 % ($p = 0.01$), and the overall trend in prevalence was significant ($p < 0.001$). Mean BHB levels over 6 months were not significantly associated with incident liver disease: ≥0.5 mmol/L (HR = 0.88, 95% CI: 0.69–1.12, p = 0.30) and ≥0.3 mmol/L (HR = 1.08, 95% CI: 0.81–1.44, p = 0.58). Similarly, HbA1c reduction was not significantly associated with risk of new onset liver disease (HR = 1.20, 95% CI: 0.94–1.55, p = 0.14).

Exploratory outcomes

Liver specific imaging, procedures and medication persistence

In the analysis of liver-specific imaging and biopsy procedures within the matched cohort, utilization was consistently lower among participants in the VINT program compared with UC. Across individual modalities such as abdominal ultrasound and CT imaging, absolute differences were modest; however, when all liver-related diagnostic procedures were combined, the overall distribution differed significantly between groups (Wilcoxon rank-sum test, $p = 0.02$; Supplementary Table S7). Similar patterns were observed in the baseline and follow-up MASLD/MASH cohort, with parallel reductions in inpatient and imaging visits and a nonsignificant trend toward lower evaluation visit rates. Medication use patterns in the MASLD/MASH baseline–follow-up cohort were broadly similar between groups (Supplementary Table S8). Resmetirom use was rare (0.3% vs 0.1%).

Discussion

In this large, claims-based matched cohort study of adults with type 2 diabetes and overweight or obesity, we observed substantially lower rates of LREs over a five-year follow-up among participants enrolled in the VINT program. Participation was associated with a 35–55% reduction in the risk of developing any liver-related diagnosis. Participants also had a 62–73% lower likelihood of developing composite MASH and advanced liver diseases, and a 68–73% lower risk of composite advanced liver disease and its complications. When expressed in absolute terms, the NNT was approximately 65 for preventing any liver-related diagnosis and 147–163 for preventing new-onset MASH and beyond or any advanced liver disease per year. These NNTs highlight the substantial population-level benefit that could be achieved if such a program were implemented broadly. Over longer follow-up periods, absolute risk reductions and NNTs are expected to improve as benefits accumulate, underscoring the long-term public health impact of scalable, nutrition-based interventions.

Pharmacologic studies have also explored primary prevention of liver disease in diabetes populations, though with different endpoints. In a Veterans Health Administration cohort, GLP-1 receptor agonists (GLP-1 RAs) were associated with a lower risk of cirrhosis, its complications, and liver-related mortality compared with DPP-4 inhibitors (HR, 0.86; 95% CI, 0.75–0.98) (22). Similarly, a Korean population-based cohort found that thiazolidinediones were linked to a lower risk of a composite NAFLD/NASH (MASLD/MASH) outcome compared with DPP-4 inhibitors, but not SGLT2 inhibitors (23). While these studies highlight pharmacologic strategies for liver disease prevention, our findings extend this evidence to a non-pharmacologic, lifestyle-based model. Although advanced liver disease events were uncommon, likely reflecting earlier disease stage, limited follow-up, and the slowly progressive nature of MASLD/MASH (24,25), VINT

participants also significantly reduced onset of composite LREs including fibrosis, cirrhosis, portal hypertension, and related complications. These trends parallel those observed in GLP-1 RA studies (22), despite differences in outcome definitions, and collectively underscore the potential of early, scalable lifestyle interventions to alter liver disease trajectories in real-world primary prevention settings. Importantly, our study cohorts were matched for specific medication utilization, suggesting the results are independent of the impact achieved through pharmacologic therapy.

Weight loss is a well-established and effective therapy for resolving MASLD, MASH, and fibrosis, and remains central to all major guideline recommendations (9–11). VINT's continuous remote-care model has demonstrated clinically meaningful and durable weight loss among adults with type 2 diabetes and overweight or obesity, with participants achieving and maintaining ~10–13% loss at two years in clinical trials (15,16) and 9–10% in real-world settings (17,18). Consistent with the landmark findings of Vilar-Gómez *et al.*, where ≥10% weight loss produced the highest rates of MASH resolution and fibrosis regression (8), our analysis showed that ≥15% weight loss was significantly associated with a lower risk of new-onset liver disease. In fact, we demonstrated a dose–response relationship between the degree of weight loss and liver disease incidence and prevalence. These findings align with a recent Cleveland Clinic retrospective cohort study of 110 patients showing that >5% weight loss reduced the risk of progression to cirrhosis among patients with obesity and MASH-related F3 fibrosis (26). Collectively, these results highlight that both the degree of weight loss and its sustainability are key to preventing liver disease progression and delaying cirrhosis onset at the population level.

Sustaining weight loss remains a major challenge in routine care due to limited time, access, and reimbursement, as well as inadequate familiarity with effective nutrition strategies

(27–31). In contrast, VINT has demonstrated long-term durability, maintaining approximately 8% weight loss over five years in adults with T2D (32,33) and 7–13% over four years in real-world cohorts (18). Sustained weight loss is critical, as improvements in steatosis, MASH resolution, and fibrosis regression are often lost with weight regain. Importantly, VINT supports patients using incretin-based therapies such as semaglutide, including deprescription pathways that help maintain weight loss (34). Consistent with these findings, the Cleveland Clinic study also emphasized that weight loss greater than 5% must be sustained for more than one year to meaningfully reduce the risk of progression from MASH-related F3 fibrosis to cirrhosis (26). Although ketone levels were not independently associated with a reduced risk of new-onset liver disease in this analysis, prior evidence indicates that higher levels of nutritional ketosis support long-term adherence and the durability of weight loss (35–37). Mechanistically, nutritional ketosis may also contribute to MASLD and MASH improvement through BHB-mediated inhibition of the NLRP3 inflammasome, enhanced insulin sensitivity, reduced hepatic de novo lipogenesis, and epigenetic modulation (38–43). Longer-term assessments of sustained ketosis are warranted to clarify its contribution to both durable weight loss and liver outcomes.

Emerging pharmacotherapies such as semaglutide and resmetirom represent important advances in MASLD and MASH management. Semaglutide produces robust weight loss and MASH resolution and fibrosis improvement, while resmetirom delivers direct hepatic benefits, including histologic improvement in inflammation and fibrosis (12,13,44). Notably, responses to resmetirom appear more pronounced when clinically meaningful weight loss (≥5%) is achieved, underscoring the additive potential of combining pharmacotherapy with structured lifestyle-based care (45). While these agents may ultimately be used in combination (46), embedding them within a lifestyle-first framework could maximize clinical benefit while minimizing the

need for prolonged dual pharmacotherapy. Importantly, the FDA and other regulatory agencies require post-approval assessments to evaluate the long-term impact of these pharmacotherapies on LREs, including progression to cirrhosis, development of PHTN, HCC, liver-related hospitalization, and liver-specific mortality (47). Prevention of these endpoints are essential for FDA full approval of emerging pharmacological therapies, beyond histologic response. Integrating such agents within structured, continuous remote-care models like VINT could offer a unique opportunity to assess both biologic efficacy and population-level effectiveness, complementing these regulatory post-marketing requirements while informing long-term liver health strategies. A key future direction will be to evaluate the initiation of agents such as resmetirom and semaglutide for patients with MASLD or MASH within a VINT-style continuous remote-care model compared with usual care.

This study has several strengths, including its large real world matched cohort design, as well as long term follow up. Robustness of the findings was supported by propensity score matching, multiple analytic strategies, and sensitivity analyses using IPTW, all of which yielded consistent results. Nonetheless, several limitations should be acknowledged. MASLD and MASH are frequently underdiagnosed in routine practice, and outcomes were defined by ICD-10 codes rather than laboratory, imaging, or biopsy criteria, which may introduce misclassification or under-ascertainment of disease. Because baseline diagnoses were assigned based on a one year pre index period, some earlier liver conditions may not have been captured; however, such missed diagnoses and under-ascertainment likely occurred similarly in both VINT and UC cohorts, minimizing differential bias but potentially underestimating the true effect. Detailed alcohol intake information during follow up was not available to include as a covariate; however, alcohol use or abuse related diagnoses were well balanced between groups in the matched

cohort, reducing the likelihood of major bias. In addition, ketone exposure was assessed only during the first six months and may not reflect longitudinal nutritional ketosis; healthcare utilization was limited to one year; and, as with all observational studies, residual confounding cannot be excluded. Finally, results may have limited generalizability beyond commercially insured populations, as nearly 90% of participants were commercially insured, though cohorts were matched on regional and sociodemographic factors.

Taken together, our findings demonstrate that participation in a structured, individualized nutrition program emphasizing carbohydrate reduction, nutritional ketosis, and continuous remote care was associated with a lower risk of incident MASLD, MASH, and advanced liver diseases, including fibrosis, cirrhosis, portal hypertension, and related complications. To our knowledge this is the first study demonstrating such important clinical benefits. These benefits were accompanied by meaningful reductions in liver-related imaging and procedures. Collectively, the results support the potential for durable lifestyle-first models to alter the clinical trajectory of liver disease and reduce system-level burden, while underscoring the need for future studies evaluating integration with emerging therapies, long-term cost-effectiveness, and post-approval drug outcomes such as cirrhosis decompensation, HCC, and liver-related mortality.

Table 1. Baseline demographics, disease trajectory as assessed by cost, and area level variables of propensity score 1:1 matched cohort of VINT and Usual Care

Characteristics	VINT (N=5,031) Mean (SD) or N (%)	UC (N=5,031) Mean (SD) or N (%)	SMD
Demographics			
Age at registration	52.9 (9.3)	53.0 (9.5)	0.01
Follow-up duration	804.8 (415.9)	684.8 (492.4)	0.26
Gender			<0.001
Female	2853 (56.7)	2853 (56.7)	
Male	2161 (43.0)	2161 (43.0)	
Unknown	17 (0.3)	17 (0.3)	
Race/Ethnicity			<0.001
White	2682 (53.3)	2682 (53.3)	
Black or African American	533 (10.6)	533 (10.6)	
Hispanic or Latino	382 (7.6)	382 (7.6)	
Asian or Pacific Islander	162 (3.2)	162 (3.2)	
Other	98 (1.9)	98 (1.9)	
Unknown	1174 (23.3)	1174 (23.3)	
Baseline Costs			
Total Cost of Care	13335.2 (25726.3)	14970.6 (31641.8)	0.06
Outpatient Cost	8020.8 (18317.3)	8799.8 (25037.2)	0.04
Inpatient Cost	1285.3 (9523.0)	1362.2 (7272.6)	0.01
Pharmacy Cost	4013.3 (11428.0)	4785.3 (13714.8)	0.06
Baseline area level variables			
Region			0.10
Midwest	1964 (39.0)	1721 (34.2)	0.10
Northeast	482 (9.6)	603 (12.0)	0.08
South	2055 (40.8)	2043 (40.6)	0.01
West	530 (10.5)	664 (13.2)	0.09
Area Deprivation Index (ADI) Quintiles			0.08
ADI 1	825 (16.4)	982 (19.5)	0.08
ADI 2	2084 (41.4)	1924 (38.2)	0.06
ADI 3	1401 (27.8)	1322 (26.3)	0.04
ADI 4	463 (9.2)	516 (10.3)	0.04
ADI 5	258 (5.1)	287 (5.7)	0.03

Note: Standardized mean differences (SMDs) and *p*-values were calculated using the TableOne package in R. For continuous variables, *p*-values were derived using the student's *t*-test when the normality assumption was met and the Wilcoxon rank-sum test otherwise. For categorical variables, *p*-values were obtained using the chi-square test or Fisher's exact test when cell counts were small. SMDs were computed as the absolute difference in means (or proportions for categorical variables) between groups divided by the pooled standard deviation. SMDs were calculated using both the TableOne and MatchIt packages to cross-validate covariate balance estimates. To evaluate covariate balance between matched groups, SMD ≤ 0.1 was used as the criterion for acceptable balance. Unlike *p*-values, which are influenced by sample size and may indicate statistically significant differences that are not clinically meaningful in large samples, SMD provides a sample size–independent measure of balance that quantifies the magnitude of difference between groups. Therefore, SMDs were used as the primary metric for assessing post-matching balance, while *p*-values were reported descriptively.
Abbreviations: UC, usual care; VINT, Individualized Nutrition Therapy (intervention) program

Table 2. Baseline comorbidities and medication use of propensity score 1:1 matched cohort of VINT and Usual Care

Characteristics	VINT (N=5,031)	UC (N=5,031)	SMD
	Mean (SD) or N (%)	Mean (SD) or N (%)	
Baseline comorbidities			
Type 2 Diabetes	2552 (50.7)	2552 (50.7)	<0.001
Obesity	1831 (36.4)	1831 (36.4)	<0.001
MASLD or MASH	255 (5.1)	255 (5.1)	<0.001
MASH	2 (0.0)	2 (0.0)	<0.001
MASLD	254 (5.0)	254 (5.0)	<0.001
Liver procedure	170 (3.4)	170 (3.4)	<0.001
Fibrosis	1 (0.0)	1 (0.0)	<0.001
Coronary Artery Disease	296 (5.9)	253 (5.0)	0.04
Any other cardiovascular disease	41 (0.8)	47 (0.9)	0.01
Stroke	80 (1.6)	85 (1.7)	0.01
Atrial Fibrillation	97 (1.9)	137 (2.7)	0.05
Heart Failure	63 (1.3)	80 (1.6)	0.03
Hyperlipidemia	2616 (52.0)	2595 (51.6)	0.01
Hypertension	2562 (50.9)	2570 (51.1)	0.003
Chronic Kidney Disease (CKD)	279 (5.5)	301 (6.0)	0.02
CKD Stage 3 and beyond	76 (1.5)	58 (1.2)	0.05
Albuminuria	121 (2.4)	118 (2.3)	0.004
Cancer	260 (5.2)	280 (5.6)	0.02
Peripheral Arterial Disease	101 (2.0)	163 (3.2)	0.08
Sleep Disorder	1375 (27.3)	1261 (25.1)	0.05
Smoking	162 (3.2)	230 (4.6)	0.07
Alcohol use/abuse diagnosis	46 (0.9)	64 (1.3)	0.03
Baseline medications			
Potential liver benefit medications or supplements	2032 (40.4)	2032 (40.4)	<0.001
Omega-3 fatty acids	37 (0.7)	43 (0.9)	0.01
Fibrates	159 (3.2)	173 (3.4)	0.02
Vitamin E	1 (0.0)	2 (0.0)	0.01
Obetocholic Acid	0 (0.0)	0 (0.0)	NA
Incretin Mimetics	975 (19.4)	975 (19.4)	<0.001
Semaglutide	465 (9.2)	527 (10.5)	0.04
Tirzepatide	86 (1.7)	164 (3.3)	0.100
Liraglutide	118 (2.3)	110 (2.2)	0.01
Dulaglutide	393 (7.8)	300 (6.0)	0.07
Exenatide	57 (1.1)	48 (1.0)	0.02
Lixisenatide	23 (0.5)	12 (0.2)	0.04
Albiglutide	1 (0.0)	3 (0.1)	0.02
SGLT2i	572 (11.4)	572 (11.4)	<0.001
Insulin	447 (8.9)	494 (9.8)	0.03
DPP4i	292 (5.8)	292 (5.8)	<0.001
Sulfonylurea	267 (5.3)	241 (4.8)	0.02
TZD	142 (2.8)	134 (2.7)	0.01
Other T2D medications	2167 (43.1)	2104 (41.8)	0.03
Anticoagulant	133 (2.6)	252 (5.0)	0.12

Antiplatelet	182 (3.6)	250 (5.0)	0.07
Beta Blocker	763 (15.2)	921 (18.3)	0.08
Calcium Channel Blocker	712 (14.2)	826 (16.4)	0.06
Diuretic	1206 (24.0)	1229 (24.4)	0.01
Other Antihypertensive	123 (2.4)	218 (4.3)	0.10
Statin	2218 (44.1)	2218 (44.1)	<0.001
Other Lipid Lowering	313 (6.2)	323 (6.4)	0.01
PCSK9i	18 (0.4)	9 (0.2)	0.04

Note: Standardized mean differences (SMDs) and *p*-values were calculated using the TableOne package in R. For continuous variables, *p*-values were derived using the student's *t*-test when the normality assumption was met and the Wilcoxon rank-sum test otherwise. For categorical variables, *p*-values were obtained using the chi-square test or Fisher's exact test when cell counts were small. SMDs were computed as the absolute difference in means (or proportions for categorical variables) between groups divided by the pooled standard deviation. SMDs were calculated using both the TableOne and MatchIt packages to cross-validate covariate balance estimates. To evaluate covariate balance between matched groups, SMD ≤ 0.1 was used as the criterion for acceptable balance. Unlike *p*-values, which are influenced by sample size and may indicate statistically significant differences that are not clinically meaningful in large samples, SMD provides a sample size–independent measure of balance that quantifies the magnitude of difference between groups. Therefore, SMDs were used as the primary metric for assessing post-matching balance, while *p*-values were reported descriptively.

Abbreviations: UC, usual care; VINT, Individualized Nutrition Therapy (intervention) program; T2D, type 2 diabetes; MASLD, metabolic dysfunction-associated steatotic liver disease; MASH, metabolic dysfunction-associated steatohepatitis; CKD, chronic kidney disease; SGLT2i, sodium–glucose cotransporter-2 inhibitor; DPP4i, dipeptidyl peptidase-4 inhibitor; RAASi, renin–angiotensin–aldosterone system inhibitor (e.g., ACEi/ARB/ARNI); MRA, mineralocorticoid receptor antagonist (steroidal); non-MRA, non-steroidal mineralocorticoid receptor antagonist (e.g., finerenone); PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor, potential drugs with liver benefits included Vitamin E, omega 3 fatty acids, fibrates, atorvastatin, rosuvastatin, and pravastatin

Table 2. Incidence rates, number needed to treat and hazard ratios for new-onset liver diagnoses, including MASH, advanced disease, fibrosis, cirrhosis and portal hypertension, under different analytic strategies.

Outcome	Analytic Strategy	VINT IR	UC IR	NNT (95% CI)	Model	HR (95% CI)	P
Any liver-related diagnosis	1	29.9	44.9	67 (42-153)	Demo	0.64 (0.55–0.75)	All <0.001
					+ Cat meds	0.62 (0.53–0.73)	
					+ Con PDC	0.45 (0.37–0.55)	
	3	29.9	44.5	68 (43-163)	Demo	0.65 (0.55–0.76)	All <0.001
					+ Cat meds	0.63 (0.53–0.74)	
					+ Con PDC	0.46 (0.38–0.56)	
MASH and beyond including advanced liver diagnosis	1	4.2	10.7	154 (96-382)	Demo	0.38 (0.27–0.56)	All <0.001
					+ Cat meds	0.34 (0.23–0.51)	
					+ Con PDC	0.28 (0.17–0.47)	
	2	4.7	11.5	147 (92-357)	Demo	0.38 (0.27–0.56)	All <0.001
					+ Cat meds	0.36 (0.25–0.53)	
					+ Con PDC	0.27 (0.17–0.44)	
	3	4.2	10.7	156 (96-397)	Demo	0.37 (0.25–0.55)	All <0.001
					+ Cat meds	0.35 (0.23–0.52)	
					+ Con PDC	0.29 (0.17–0.47)	
Advanced liver diagnosis	1	2.8	9.0	163 (104-367)	Demo	0.30 (0.19–0.47)	All <0.001
					+ Cat meds	0.27 (0.17–0.44)	
					+ Con PDC	0.28 (0.16–0.51)	
	2	3.3	9.7	156 (99-348)	Demo	0.32 (0.21–0.49)	All <0.001
					+ Cat meds	0.29 (0.19–0.46)	
					+ Con PDC	0.27 (0.16–0.46)	
	3	2.9	9.0	163 (104-367)	Demo	0.30 (0.19-0.48)	All <0.001
					+ Cat meds	0.28 (0.17-0.45)	
					+ Con PDC	0.29 (0.16-0.51)	

Note: Incidence rates are reported as events per 1,000 person years. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models. The "Demo" model was adjusted for age, sex, and race or ethnicity. The "+ Cat meds" and "+ Con PDC" models additionally adjusted for follow up medication use, including SGLT2 inhibitors, GLP1 receptor agonists, thiazolidinediones, statins, and other medications or supplements with potential liver benefits, modeled both as categorical ever or never use and as continuous proportion of days covered (PDC). All models also accounted for baseline diagnoses of type 2 diabetes and obesity. VINT refers to participants enrolled in the Individualized Nutrition Therapy program, and UC refers to usual care.

Figure Legends

Figure 1. Flow diagram depicting patient selection and attrition from the initial Komodo Healthcare Sentinel cohort to the final matched analytic sample.

Figure 2. Cumulative incidence curves for new-onset of all liver diagnoses under (A) analytic strategy 1 (incident disease cohort), (B) analytic strategy 3 (incident disease cohort with maximally restricted baseline), new-onset of MASH and beyond under (C) analytic strategy 1 (incident disease cohort), (D) analytic strategy 2 (incident disease cohort and potential baseline MASLD progression), new-onset of fibrosis, cirrhosis and/or portal hypertension (E) analytic strategy 1 (incident disease cohort), (F) analytic strategy 2 (incident disease cohort and potential baseline MASLD progression). Curves are displayed up to 4 years to aid interpretability, given the decreasing sample size late in follow-up, though all analyses were conducted using the full observation window with standard right-censoring.

Figure 3. Distribution of liver diagnoses observed after index or enrollment, compiled as events contributing to the primary composite outcomes under (A) Analytic Strategy 1, (B) Analytic Strategy 2, and (C) Analytic Strategy 3.

Figure 4. Dose-response relationship between the level of weight loss category in VINT versus UC in (A) incidence rates of any liver diagnoses onset (B) prevalence of any liver diagnoses during follow-up

Figure 1. Flow diagram depicting patient selection and attrition from the initial Komodo Healthcare Sentinel cohort to the final matched analytic sample.



Figure 2. Cumulative incidence curves for new-onset of all liver diagnoses under (A) analytic strategy 1 (incident disease cohort), (B) analytic strategy 3 (incident disease cohort with maximally restricted baseline), new-onset of MASH and beyond under (C) analytic strategy 1 (incident disease cohort), (D) analytic strategy 2 (incident disease cohort and potential baseline MASLD progression), new-onset of fibrosis, cirrhosis and/or portal hypertension (E) analytic strategy 1 (incident disease cohort), (F) analytic strategy 2 (incident disease cohort and potential baseline MASLD progression). Curves are displayed up to 4 years to aid interpretability, given the decreasing sample size late in follow-up, though all analyses were conducted using the full observation window with standard right-censoring.



C.


Cumulative Incidence (%)
8.0
6.0
4.0
2.0
0.0
0
1
2
3
4
Time (years)
Strata
Number at risk
UC 4582 2957 1520 715 335
VINT 4589 3986 2264 762 343
Time (years)
Strata UC VINT

D.


Cumulative Incidence (%)
8.0
6.0
4.0
2.0
0.0
0
1
2
3
4
Time (years)
Strata
Number at risk
UC 4426 2887 1497 708 333
VINT 4449 3865 2199 746 340
Time (years)
Strata UC VINT

E.


Cumulative Incidence (%)
6.0
4.0
2.0
0.0
0
1
2
3
4
Time (years)
Strata
Number at risk
UC 4408 2875 1492 708 333
VINT 4435 3858 2195 744 339
Time (years)
Strata UC VINT

F.


Cumulative Incidence (%)
6.0
4.0
2.0
0.0
0
1
2
3
4
Time (years)
Strata
Number at risk
UC 4563 2945 1515 715 335
VINT 4574 3979 2260 760 342
Time (years)
Strata UC VINT

Figure 3. Distribution of liver diagnoses observed after index or enrollment, compiled as events contributing to the primary composite outcomes under (A) Analytic Strategy 1, (B) Analytic Strategy 2, and (C) Analytic Strategy 3.

A.



B.



C.



Figure 4. Dose-response relationship between the level of weight loss category in VINT versus UC in (A) incidence rates of any liver diagnoses onset (B) prevalence of any liver diagnoses during follow-up

A.



B.



References

1. Xia Y, Zhang L, et al. Prevalence of metabolic dysfunction-associated fatty liver disease in the United States: NHANES 2017–2020 analysis. *J Hepatol*. 2025;73(2):450–459. doi:10.1016/j.jhep.2025.01.015
2. Younossi ZM, Stepanova M, et al. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults with type 2 diabetes in the United States. *Diabetes Care*. 2025;48(3):555–564. doi:10.2337/dc24-1984
3. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety statement on MASLD/MASH: prevalence, risk, and management. *Hepatology*. 2024;79(4):1170–1185. doi:10.1002/hep.33105
4. Ciardullo S, Perseghin G. Prevalence of NAFLD and advanced fibrosis in overweight and obese US adults: NHANES elastography study. *Liver Int*. 2024;44(3):512–520. doi:10.1111/liv.15632
5. Estes C, Anstee QM, et al. Modeling the burden of NASH and advanced fibrosis in the United States using NHANES. *Hepatol Commun*. 2024;8(5):713–724. doi:10.1002/hep4.237
6. Younossi ZM, Blachier M, Li C, et al. The economic and clinical burden of nonalcoholic steatohepatitis in the United States. *Hepatology*. 2016;64(1):73–84. doi:10.1002/hep.28477
7. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease and its impact on advanced liver disease and mortality in the United States. *Hepatology*. 2018;67(1):123–133. doi:10.1002/hep.29466
8. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. *Gastroenterology*. 2015;149(2):367–378.e5. doi:10.1053/j.gastro.2015.04.005
9. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology*. 2018;67(1):328–357. doi:10.1002/hep.29367
10. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. *Hepatology*. 2023;77(5):1797–1835. doi:10.1097/HEP.0000000000000323
11. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol*. 2016;64(6):1388–1402. doi:10.1016/j.jhep.2015.11.004
12. Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, et al; MAESTRO-NASH Investigators. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. *N Engl J Med*. 2024;390(6):497–509. doi:10.1056/NEJMoa2309000
13. Sanyal AJ, Newsome PN, Kliers I, et al; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. *N Engl J Med*. 2025;392(21):2089–2099. doi:10.1056/NEJMoa2413258
14. Hallberg SJ, McKenzie AL, Williams PT, et al. Effectiveness and safety of a novel care model for the management of type 2 diabetes at 1 year: an open-label, nonrandomized, controlled study. *Diabetes Ther*. 2018;9(2):583–612. doi:10.1007/s13300-018-0373-9
15. Athinarayanan SJ, Adams RN, Hallberg SJ, et al. Long-term effects of a novel continuous remote care intervention including nutritional ketosis for the management of type 2 diabetes: a 2-year nonrandomized clinical trial. *Front Endocrinol (Lausanne)*. 2019;10:348. doi:10.3389/fendo.2019.00348
16. McKenzie AL, Athinarayanan SJ, McCue J, et al. Type 2 diabetes prevention focused on normalization of glycemia: a two-year pilot study. *Nutrients*. 2021;13(3):749. doi:10.3390/nu13030749

17. Roberts CGP, Athinarayanan SJ, Volk BM, Adams RN. One-year real-world outcomes of remotely delivered carbohydrate-restricted nutrition therapy. *Obesity (Silver Spring)*. 2024;32(1):55–308. doi:10.1002/oby.24195
18. Athinarayanan SJ, Shanmugam PV, Roberts CGP. Cost-effective long-term weight loss and maintenance via nutritional ketosis and telemedicine, without GLP1ra. [embargoed].
19. Vilar-Gomez E, Athinarayanan SJ, Adams RN, et al. Post hoc analyses of surrogate markers of nonalcoholic fatty liver disease and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, nonrandomized controlled study. *BMJ Open*. 2019;9(3):e023597. doi:10.1136/bmjopen-2018-023597
20. Khan T, Kim C, Druet A. High burden, low priority? Iron deficiency anemia in U.S. women and the challenges of data gaps with over-the-counter treatments. *Komodo Insights* 9 Oct 2023. https://www.komodohealth.com/insights/high-burden-low-priority-iron-deficiency-anemia-in-u.s-women-and-the-challenges-of-data-gaps-with-over-the-counter-treatment (accessed 15 Oct 2025).
21. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative.The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ*. 2007;335(7624):806–808. doi:10.1136/bmj.39335.541782.AD
22. Kanwal F, Kramer JR, Li L, et al. GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction–associated steatotic liver disease. *JAMA Intern Med*. 2024;184(11):1314–1323. doi:10.1001/jamainternmed.2024.4661
23. Jung C, Park S, Kim H. Association between hypoglycemic agent use and the risk of occurrence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. *PLoS One*. 2023;18(11):e0294423. doi:10.1371/journal.pone.0294423
24. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. *Hepatology*. 2017;65(5):1557–1565.
25. Younossi ZM, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors, and prevention. *Nat Rev Gastroenterol Hepatol*. 2018;15(1):11–20. doi:10.1038/nrgastro.2017.109
26. Niu J, Al-Yaman W, Pinyopornpanish K, et al. The long-term effect of weight loss on the prevention of progression to cirrhosis among patients with obesity and MASH-related F3 liver fibrosis. *Int J Environ Res Public Health*. 2024;21(6):708. doi:10.3390/ijerph21060708
27. Perreault L, Kramer ES, Smith PC, et al. A closer look at weight loss interventions in primary care: a systematic review and meta-analysis. *Front Med (Lausanne)*. 2023;10:1204849. doi:10.3389/fmed.2023.1204849
28. Pagoto S, et al. An evidence-based guide for obesity treatment in primary care. *Am J Med*. 2015;128(10):e11–e19. doi:10.1016/j.amjmed.2015.07.015
29. Oshman L, Othman A, Furst W, et al. Primary care providers' perceived barriers to obesity treatment and opportunities for improvement: a mixed methods study. *PLoS One*. 2023;18(4):e0284474. doi:10.1371/journal.pone.0284474
30. Dudekula A, Rachakonda V, Shaik B, Behari J. Weight loss in nonalcoholic fatty liver disease: clinical outcomes and predictors of success. *PLoS One*. 2014;9(11):e111808. doi:10.1371/journal.pone.0111808
31. Hallsworth K, Adams LA. Lifestyle modification in NAFLD/NASH: facts and figures. *JHEP Rep*. 2019;1(6):468–479. doi:10.1016/j.jhepr.2019.10.008
32. McKenzie AL, Athinarayanan SJ, Van Tieghem MR, et al. Five-year effects of a novel continuous remote care model with carbohydrate-restricted nutrition therapy including nutritional ketosis in type 2 diabetes: an extension study. *Diabetes Res Clin Pract*. 2024;217:111898. doi:10.1016/j.diabres.2024.111898
33. Adams RN, Athinarayanan SJ, Zoller AR, McKenzie AL, Ratner RE. Sustained metabolic improvements in a remotely delivered ketogenic nutrition program for veterans with type 2

diabetes: a 3-year observational study. *Diabetes Obes Metab*. 2025;27(1):e16525. doi:10.1111/dom.16525
34. McKenzie AL, Athinarayanan SJ. Impact of glucagon-like peptide-1 agonist deprescription in type 2 diabetes in a real-world setting: a propensity score–matched cohort study. *Diabetes Ther*. 2024;15(10):1–11. doi:10.1007/s13300-024-01547-0
35. Finucane FM, Rafey MF, Leahy M, et al. Weight loss is proportional to increases in fasting serum β-hydroxybutyrate concentrations in adults with severe obesity undergoing a low-energy meal replacement program. *Hum Nutr Metab*. 2023;200192. doi:10.1016/j.hnm.2023.200192
36. McKenzie AL, Athinarayanan SJ, Adams RN, et al. Mean blood β-hydroxybutyrate predicts clinically significant weight loss following 90 days of carbohydrate-restricted nutrition therapy. *Diabetes*. 2021;70(suppl 1):307-OR. doi:10.2337/db21-307-OR
37. Adams RN, Athinarayanan SJ, Roberts CGP, Volk BM. Real-world ketone targets in carbohydrate-restricted nutrition therapy for obesity. *Obesity (Silver Spring)*. 2024;32(1):55–308. doi:10.1002/oby.24195
38. Youm YH, Nguyen KY, Grant RW, et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome–mediated inflammatory disease. *Nat Med*. 2015;21(3):263–269. doi:10.1038/nm.3804
39. Goldberg EL, Molony RD, Kudo E, et al. Ketogenesis activates metabolically protective γδ T cells in visceral adipose tissue. *Cell Metab*. 2020;31(3):420–436.e7. doi:10.1016/j.cmet.2020.01.009
40. Mardinoglu A, Wu H, Bjornson E, et al. An integrated understanding of the rapid metabolic benefits of a carbohydrate-restricted diet on hepatic steatosis in humans. *Cell Metab*. 2018;27(3):559–571.e5. doi:10.1016/j.cmet.2018.01.005
41. Hyde PN, Newsom SA, Sapper TN, et al. Dietary carbohydrate restriction improves metabolic syndrome independent of weight loss. *JCI Insight*. 2019;4(12):e128308. doi:10.1172/jci.insight.128308
42. Shimazu T, Hirschey MD, Newman J, et al. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. *Science*. 2013;339(6116):211–214. doi:10.1126/science.1227166
43. Puchalska P, Crawford PA. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. *Cell Metab*. 2017;25(2):262–284. doi:10.1016/j.cmet.2016.12.022
44. Harrison SA, Taub R, Neff GW, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. *Nat Med*. 2023;29(11):2919–2928. doi:10.1038/s41591-023-02603-1
45. Effect of Resmetirom or Placebo in NASH Fibrosis Patients With <5% or >5% Weight Loss and/or on Baseline GLP-1 Therapy in the MAESTRO-NASH 52-Week Serial Liver Biopsy Study. Gastroenterol Hepatol (N Y). 2024;20(12 Suppl 11):8–9.
46. Zhou XD, Wong VWS, Zheng MH. Resmetirom and GLP-1 agonists for MASH: complementary rather than exclusive. *NPJ Gut Liver*. 2024;1:4. doi:10.1038/s44355-024-00004-w
47. U.S. Food and Drug Administration (FDA). *Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment—Guidance for Industry.* Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration; 2018. Available at: https://www.fda.gov/media/119044/download

Data Availability

The datasets used in this study are not publicly available due to licensing restrictions. They were obtained under a commercial agreement with the data vendor and may only be accessed in accordance with the terms of that license.

Compliance with Ethics Guidelines

This study was deemed exempt from institutional review board (IRB) oversight because it utilized only retrospective, de-identified data and did not involve any direct interaction or intervention with human participants.